Use of brimonidine for preventing and reducing the severity of stress-associated conditions

Details for Australian Patent Application No. 2004253500 (hide)

Owner Allergan, Inc.

Inventors Whitcup, Scott M.; Brin, Mitchell F.; Gil, Daniel W.; Donello, John E.

Agent Davies Collison Cave

Pub. Number AU-A-2004253500

PCT Pub. Number WO2005/002580

Priority 10/607,439 25.06.03 US

Filing date 22 June 2004

Wipo publication date 13 January 2005

International Classifications

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/002580 Priority application(s): WO2005/002580

16 December 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253501-Apparatus and method for bioelectric stimulation, healing acceleration, pain relief, or pathogen devitalization

2004253499-Method of improving animal tissue quality by supplementing the animal diet with mixed tocotrienols